Treatment of experimental autoimmune uveoretinitis with atorvastatin and lovastatin.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Experimental Eye Research

• Publication date

  2007-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.EXER.2006.11.011PMID 17208229
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multiplex cytokine detection versus ELISA for aqueous humor: IL-5, IL-10, and IFNgamma profiles in uveitis.

  2006cited by this paper
• Treatment of experimental autoimmune uveoretinitis with poly(lactic acid) nanoparticles encapsulating betamethasone phosphate.

  2006cited by this paper
• Effect of atorvastatin (80 mg/day) versus pravastatin (40 mg/day) on arterial remodeling at coronary branch points (from the REVERSAL study).

  2005cited by this paper
• Induction of nestin, Ki-67, and cyclin D1 expression in Müller cells after laser injury in adult rat retina

  2005cited by this paper
• Evaluation of HMG-CoA Reductase Inhibitors for Multiple Sclerosis

  2005cited by this paper
• Suppression of Autoimmune Retinal Disease by Lovastatin Does Not Require Th2 Cytokine Induction1

  2005cited by this paper
• The effects of atorvastatin in experimental autoimmune uveitis

  2005cited by this paper
• Ocular transfer of retinal glial cells transduced ex vivo with adenovirus expressing viral IL-10 or CTLA4-Ig inhibits experimental autoimmune uveoretinitis

  2003cited by this paper
• Suppression of experimental autoimmune uveoretinitis by anti-alphabeta TCR monoclonal antibody.

  2002cited by this paper
• TH1 AND TH2 RESPONSES IN PATHOGENESIS AND REGULATION OF EXPERIMENTAL AUTOIMMUNE UVEORETINITIS

  2002cited by this paper
• The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

  2002cited by this paper
• Suppression of Experimental Autoimmune Uveoretinitis by Anti-αβ TCR Monoclonal Antibody

  2002cited by this paper
• Retinal microenvironment controls resident and infiltrating macrophage function during uveoretinitis.

  2002cited by this paper
• Type I interferons as immunoregulatory molecules; implications for therapy in experimental autoimmune uveoretinitis.

  2002cited by this paper
• Effect of Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitor Therapy on High Sensitive C-Reactive Protein Levels

  2001cited by this paper
• Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site

  2001cited by this paper
• Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis

  2001cited by this paper
• Aqueous and Serum Interferon γ, Interleukin (IL) 2, IL-4, and IL-10 in Patients With Uveitis

  2000cited by this paper
• Statins as a newly recognized type of immunomodulator

  2000cited by this paper
• Aqueous and serum interferon gamma, interleukin (IL) 2, IL-4, and IL-10 in patients with uveitis.

  2000cited by this paper
• Metabolism and excretion of atorvastatin in rats and dogs.

  1999cited by this paper
• Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin.

  1999cited by this paper
• Marrow-derived activated macrophages are required during the effector phase of experimental autoimmune uveoretinitis in rats.

  1998cited by this paper
• Metabolism and excretion studies in mouse after single and multiple oral doses of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin.

  1998cited by this paper
• Effect of macrophage depletion by liposomes containing dichloromethylene-diphosphonate on endotoxin-induced uveitis.

  1998cited by this paper
• Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages.

  1997cited by this paper
• Blood‐retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: Comparison with vascular endothelial growth factor, tumor necrosis factor α, and interleukin‐1β‐mediated breakdown

  1997cited by this paper
• Multiple‐dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG‐CoA reductase, in healthy subjects

  1996cited by this paper
• Resident and infiltrating immune cells in the uveal tract in the early and late stages of experimental autoimmune uveoretinitis.

  1996cited by this paper
• Effect of pravastatin on outcomes after cardiac transplantation.

  1995cited by this paper
• Role of mevalonic acid in the regulation of natural killer cell cytotoxicity

  1989cited by this paper
• Glial retinal Müller cells produce IL-1 activity and have a dual effect on autoimmune T helper lymphocytes. Antigen presentation manifested after removal of suppressive activity.

  1988cited by this paper
• S-antigen: identification of the MAbA9-C6 monoclonal antibody binding site and the uveitopathogenic sites.

  1986cited by this paper

• Can Simvastatin Reduce the Need for Immunomodulatory Drugs to Treat Uveitis?

  2023cites this paper
• Combined Therapy of Experimental Autoimmune Uveitis by a Dual-Drug Nanocomposite Formulation with Berberine and Dexamethasone

  2023cites this paper
• Journal Pre-proof Can simvastatin reduce the need for immunomodulatory drugs to treat uveitis? A prospective, randomized, placebo-controlled trial

  2023cites this paper
• Effects of atorvastatin on the function of Tenon’s capsule fibroblasts in human eyes

  2023cites this paper
• Decreased risk of non-infectious anterior uveitis with statin therapy in a large healthcare claims database

  2021cites this paper
• Chitosan-Coated PLGA Nanoparticles for Enhanced Ocular Anti-Inflammatory Efficacy of Atorvastatin Calcium

  2020cites this paper
• Remission Of Non-Infectious Anterior Scleritis: Incidence And Predictive Factors.

  2019cites this paper
• Statins in ophthalmology.

  2019cites this paper
• Therapeutic approaches to prevent disease recurrence in uveitis

  2019cites this paper
• Atorvastatin misuse alters histological and protein expression in the hippocampal CA3 region of male rat models

  2018cites this paper
• ‘Statins in retinal disease’

  2018cites this paper
• Immunotropic Effects and Proposed Mechanism of Action for 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Inhibitors (Statins)

  2018cites this paper
• Diagnostic and therapeutic challenges.

  2017cites this paper
• Fisetin inhibits liver cancer growth in a mouse model: Relation to dopamine receptor

  2017cites this paper
• Simvastatin as an Adjunct to Conventional Therapy of Non-infectious Uveitis: A Randomized, Open-Label Pilot Study

  2017cites this paper
• Effect of Lovastatin on Wound-Healing Modulation After Glaucoma Filtration Surgery in a Rabbit Model.

  2016cites this paper
• Short Term, Low Dose Simvastatin Pretreatment Alters Memory Immune Function Following Secondary Staphylococcus aureus Infection.

  2016cites this paper
• Treatment of experimental autoimmune uveoretinitis with different natural compounds

  2016cites this paper
• Association between statin use and uveitis: results from the Pacific Ocular Inflammation study.

  2014cites this paper
• Role of statins in the treatment of multiple sclerosis.

  2014cites this paper
• Statin Modulation of Human T-Cell Proliferation, IL-1β and IL-17 Production, and IFN-γ T Cell Expression: Synergy with Conventional Immunosuppressive Agents

  2013cites this paper
• β-Arrestins as Potential Therapeutic Targets for Alzheimer’s Disease

  2013cites this paper
• Statin use and ocular inflammatory disease risk

  2013cites this paper
• Statin-Mediated Attenuation of Chemokine Expression in Peripheral Nerve Vascular Endothelial Cells

  2012cites this paper
• Impact of HMG‐CoA reductase inhibition on oxidant‐induced injury in human retinal pigment epithelium cells

  2011cites this paper
• Diagnostic and therapeutic challenges. Acute onset panuveitis.

  2010cites this paper
• Role of DAF in protecting against T-cell autoreactivity that leads to experimental autoimmune uveitis.

  2009cites this paper
• Immunomodulation by statins: mechanisms and potential impact on autoimmune diseases

  2009cites this paper
• DAF Protects Against T Cell Autoreactivity That Leads to Experimental Autoimmune Uveitis

  2009cites this paper
• Immunomodulator activity of 3-hydroxy-3-methilglutaryl-CoA inhibitors.

  2009cites this paper
• Staphylococcal enterotoxin B is involved in aggravation and recurrence of murine experimental autoimmune uveoretinitis via Vbeta8+CD4+ T cells.

  2009cites this paper
• Glucocorticoids regulate innate immunity in a model of multiple sclerosis: reciprocal interactions between the A1 adenosine receptor and β‐arrestin‐1 in monocytoid cells

  2008cites this paper
• Functional Cellular Responses and Cytokine Profiles

  2008cites this paper